•A significant reduction in disease flares in both groups - colchicineresistant pts. and pts. with amyloidosis•Dose reduction required in patients with amyloidosis and chronickidney disease•Limited effect of IL-1 inhibition on nephrotic syndrome. Here, IL1B is linked to amyloidosis.